@article{bc8f1477034c43a9abeb7b18a07d3284,
title = "Vaccine protection against the SARS-CoV-2 Omicron variant in macaques",
abstract = "The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. In this study, we show that the mRNA-based BNT162b2 vaccine and the adenovirus-vector-based Ad26.COV2.S vaccine provide robust protection against high-dose challenge with the SARS-CoV-2 Omicron variant in cynomolgus macaques. We vaccinated 30 macaques with homologous and heterologous prime-boost regimens with BNT162b2 and Ad26.COV2.S. Following Omicron challenge, vaccinated macaques demonstrated rapid control of virus in bronchoalveolar lavage, and most vaccinated animals also controlled virus in nasal swabs. However, 4 vaccinated animals that had moderate Omicron-neutralizing antibody titers and undetectable Omicron CD8+ T cell responses failed to control virus in the upper respiratory tract. Moreover, virologic control correlated with both antibody and T cell responses. These data suggest that both humoral and cellular immune responses contribute to vaccine protection against a highly mutated SARS-CoV-2 variant.",
keywords = "Omicron, SARS-CoV-2, macaque",
author = "Abishek Chandrashekar and Jingyou Yu and Katherine McMahan and Catherine Jacob-Dolan and Jinyan Liu and Xuan He and David Hope and Tochi Anioke and Julia Barrett and Benjamin Chung and Hachmann, {Nicole P.} and Michelle Lifton and Jessica Miller and Olivia Powers and Michaela Sciacca and Daniel Sellers and Mazuba Siamatu and Nehalee Surve and Haley VanWyk and Huahua Wan and Cindy Wu and Laurent Pessaint and Daniel Valentin and {Van Ry}, Alex and Jeanne Muench and Mona Boursiquot and Anthony Cook and Jason Velasco and Elyse Teow and Boon, {Adrianus C.M.} and Suthar, {Mehul S.} and Neharika Jain and Martinot, {Amanda J.} and Lewis, {Mark G.} and Hanne Andersen and Barouch, {Dan H.}",
note = "Funding Information: The authors thank S. Ducat, T. Hayes, A. Goode, G. Romero, J. Yalley-Ogunro, M. Cabus, B. Narvaez, E. Bouffard, S. Gardner, M. Gebre, V. Giffin, and Y. Tian for generous advice, assistance, and reagents. We thank MesoScale Discovery for providing the ECLA kits. Funding: we acknowledge NIH contract 75N93021C00014 , NIH grant CA260476 , the Massachusetts Consortium for Pathogen Readiness , the Ragon Institute , and the Musk Foundation (D.H.B.) and NIH contract 75N93021C00016 (A.C.M.B.). Funding Information: D.H.B. is a co-inventor on provisional vaccine patents licensed to Janssen (63/121,482; 63/133,969; 63/135,182) and serves as a consultant to Pfizer. The authors report no other conflict of interest. A.C.M.B. has received funding from Abbvie for the commercial development of SARS-CoV-2 mAbs. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = apr,
day = "28",
doi = "10.1016/j.cell.2022.03.024",
language = "English",
volume = "185",
pages = "1549--1555.e11",
journal = "Cell",
issn = "0092-8674",
number = "9",
}